anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In a U.S. multicenter, double-blind trial in adult outpatients with endoscopically confirmed duodenal ulcer (DU), orally administered PEPCID was compared to placebo. As shown in Table 4, 70% of patients treated with PEPCID 40 mg at bedtime were healed by Week 4. Most patients’ DU healed within 4 weeks. 

Patients not healed by Week 4 were continued in the trial. By Week 8, 83% of patients treated with PEPCID had healed DU, compared to 45% of patients treated with placebo. The incidence of DU healing with PEPCID was greater than with placebo at each time point based on proportion of endoscopically confirmed healed DUs. Trials have not assessed the safety of PEPCID in uncomplicated active DU for periods of more than 8 weeks.

In this study, time to relief of daytime and nocturnal pain was shorter for patients receiving PEPCID than for patients receiving placebo; patients receiving PEPCID also took less antacid than patients receiving placebo.
FIELD: biotechnologies. ^ SUBSTANCE: invention relates to field of biotechnology, namely to obtaining vaccine strains, and can be used in veterinary. Bacterium Actinobacillus pleuropneumoniae is modified by introducing deletion, of at least one segment of gene apxIA and, optionally, segment of gene apxIIA, which code transmembrane domain of haemolytic and cytolytic exotoxins Apx. Obtained bacterium is used for production of vaccine against pig pleuropneumonia. ^ EFFECT: invention allows obtaining attenuated live vaccine against pig pleuropneumonia based on immunogenic non-haemolytic strain of bacterium Actinobacillus pleuropneumoniae. ^ 11 cl, 6 dwg, 3 tbl, 1 ex
This will be a single institution phase I study with an expansion cohort. Up to 2 dose levels of daily afatinib will be studied: 30 mg/day and 40 mg/day. The doses of ribavirin, carboplatin, and paclitaxel are fixed. A standard 3 + 3 phase I dose escalation design will be used.
Perforation is the most dangerous complication of gastroduodenal ulcer disease. It accounts for more than 70% of deaths associated with peptic ulcer disease. In addition to age and concomitant disease, intervention related complications are statistically significant predictors of death after hospital stay. Age, time to presentation and comorbidities are not factors that can be influenced. If it would be possible to reduce the impact of procedure related complications or the "second hit", that may lead to decreased morbidity and mortality.

This will be a pilot clinical study to evaluate the safety and feasibility of endoscopic translumenal omental patch closure. Patients with the clinical diagnosis of a perforated viscus who are scheduled to undergo surgical exploration will be recruited. Endoscopic translumenal omental patch will be attempted first if the patient has no contraindication. Should this prove unsuccessful, the surgical team will proceed with conversion to laparoscopic or open standard surgical therapy as indicated.
Macrophage transition from an inflammatory to reparative phenotype after tissue injury is controlled by epigenetic enzymes that regulate inflammatory gene expression. We have previously identified that the histone methyltransferase SETDB2 in macrophages drives tissue repair by repressing NF-κB-mediated inflammation. Complementary ATAC-Seq and RNA-Seq of wound macrophages isolated from mice deficient in SETDB2 in myeloid cells revealed that SETDB2 suppresses the inflammatory gene program by inhibiting chromatin accessibility at NF-κB-dependent gene promoters. We found that STAT3 was required for SETDB2 expression in macrophages, yet paradoxically, it also functioned as a binding partner of SETDB2 where it repressed SETDB2 activity by inhibiting its interaction with the NF-κB component, RELA, leading to increased RELA/NF-κB-mediated inflammatory gene expression. Furthermore, RNA-Seq in wound macrophages from STAT3-deficient mice corroborated this and revealed STAT3 and SETDB2 transcriptionally coregulate overlapping genes. Finally, in diabetic wound macrophages, STAT3 expression and STAT3/SETDB2 binding were increased. We have identified what we believe to be a novel STAT3/SETDB2 axis that modulates macrophage phenotype during tissue repair and may be an important therapeutic target for nonhealing diabetic wounds.
Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B12 therapy and who have no nervous system involvement.

Nascobal Nasal Spray is also indicated as a supplement for other vitamin B12 deficiencies, including: 

I. Dietary deficiency of vitamin B12 occurring in strict vegetarians (Isolated vitamin B12 deficiency is very rare).

II. Malabsorption of vitamin B12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B12 deficiency.

III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B12 deficiency. Structural lesions leading to vitamin B12 deficiency include regional ileitis, ileal resections, malignancies, etc.

IV. Competition for vitamin B12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B12 or folate. 

V. Inadequate utilization of vitamin B12. This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia.

Requirements of vitamin B12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. 

Nascobal Nasal Spray is not suitable for vitamin B12 absorption test (Schilling Test).
At the end of the randomized treatment, Phase 2 participants will be given the option to participate in the Extension Phase. Phase 2 Treatment Group 1 will switch to GS-1720/GS-4182 FDC weekly. Phase 2 Treatment Group 2 will receive a loading dose of GS-1720/GS-4182 FDC on Extension Phase Day 1 then, GS-1720/GS-4182 FDC weekly. Participants who choose to enter the Extension Phase will receive GS-1720/GS-4182 FDC tablets until the product becomes available or until Gilead Sciences elects to discontinue the study, whichever occurs first.
The present invention relates to an anticancer medical composition which belongs to the technical field of drugs. Anticancer effective components comprise anticancer antibiotics and guanine derivatives, wherein the guanine derivatives can suppress the DNA repair function in cells, and reduce the tolerance of tumor cells for the anticancer antibiotics. Medicinal supplementary materials mainly comprise high molecular biologic capacitability polymers which can be degraded and absorbed, and in the degradation and absorption processes, anticancer drugs can be slowly released at part of a tumor, so that the systemic toxicity reactions of the drugs are reduced obviously. Simultaneously, the effective drug concentration can be kept at part of the tumor. The anticancer medical composition can be put at part of the tumor, the systemic toxicity reactions of the drugs can be reduced, and simultaneously the drug concentration of part of the tumor can be enhanced in a selective mode. The treatment effect of non-operative treatment modes, such as chemotherapeutics, radiotherapy, etc., can be enhanced.
A composition for preventing an adhesion is provided to play a role of a film for preventing an adhesion by making a solution of a sol state to a gel by a body temperature and coating it in an organization stably and to prevent product absorbed in a body or disassembled from being adhered secondly by disassembling it into a surfactant of a low molecular weight and a monomolecular material of biodegradable as time passes. A composition for preventing an adhesion is a composition containing a polymer having temperature sensitivity, being water-soluble, and showing a sol-gel phase transition by temperature. The polymer is phase-transited from sol state to gel state by a body temperature, is coated within an organization stably, plays a role of a film for preventing an adhesion and is manufactured by connecting two block copolymers or more by a dicarboxyl group linker. The two block copolymers are the group are selected from a group consisting of a polyethylene oxide(PEO)-polypropylene oxide(PPO)-polyethylene oxide(PEO) block copolymer and a polyethylene oxide(PEO)-polybutylene oxide(PBO)-polyethylene oxide(PEO) block copolymer. An average molecular weight of the block copolymer is 1000-20000 dalton. A total average molecular weight of the multi-block copolymer is 25,000-1,000,000 dalton.
Carcinogenesis 

Lifetime carcinogenicity studies were conducted with ziprasidone in Long Evans rats and CD-1 mice. Ziprasidone was administered for 24 months in the diet at doses of 2, 6, or 12 mg/kg/day to rats, and 50, 100, or 200 mg/kg/day to mice (0.1 to 0.6 and 1 to 5 times the maximum recommended human dose (MRHD) of 200 mg/day based on mg/m 2 body surface area, respectively). In the rat study, there was no evidence of an increased incidence of tumors compared to controls. In male mice, there was no increase in incidence of tumors relative to controls. In female mice, there were dose-related increases in the incidences of pituitary gland adenoma and carcinoma, and mammary gland adenocarcinoma at all doses tested (50 to 200 mg/kg/day or 1 to 5 times the MRHD based on mg/m2 body surface area). Proliferative changes in the pituitary and mammary glands of rodents have been observed following chronic administration of other antipsychotic agents and are considered to be prolactin-mediated. Increases in serum prolactin were observed in a 1-month dietary study in female, but not male, mice at 100 and 200 mg/kg/day (or 2.5 and 5 times the MRHD based on a mg/m2 body surface area). Ziprasidone had no effect on serum prolactin in rats in a 5-week dietary study at the doses that were used in the carcinogenicity study. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown [see Warnings and Precautions (5.14)].

Mutagenesis 

Ziprasidone was tested in the Ames bacterial mutation assay, the in vitro mammalian cell gene mutation mouse lymphoma assay, the in vitro chromosomal aberration assay in human lymphocytes, and the in vivo chromosomal aberration assay in mouse bone marrow. There was a reproducible mutagenic response in the Ames assay in one strain of S. typhimurium in the absence of metabolic activation. Positive results were obtained in both the in vitro mammalian cell gene mutation assay and the in vitro chromosomal aberration assay in human lymphocytes.

Impairment of Fertility

Ziprasidone was shown to increase time to copulation in Sprague-Dawley rats in two fertility and early embryonic development studies at doses of 10 to 160 mg/kg/day (0.5 to 8 times the MRHD of 200 mg/day based on mg/m2 body surface area). Fertility rate was reduced at 160 mg/kg/day (8 times the MRHD based on mg/m2 body surface area). There was no effect on fertility at 40 mg/kg/day (2 times the MRHD based on mg/m2 body surface area). The effect on fertility appeared to be in the female since fertility was not impaired when males given 160 mg/kg/day (8 times the MRHD based on mg/m2 body surface area) were mated with untreated females.
Table 6 presents pharmacokinetic data from clinical trials and a published study in pediatric patients (< 1 year of age; N=27) given famotidine IV 0.5 mg/kg and from published studies of small numbers of pediatric patients (1 to 15 years of age) given famotidine intravenously. Areas under the curve (AUCs) are normalized to a dose of 0.5 mg/kg IV for pediatric patients 1 to 15 years of age and compared with an extrapolated 40 mg intravenous dose in adults (extrapolation based on results obtained with a 20 mg IV adult dose). 

Plasma clearance is reduced and elimination half-life is prolonged in pediatric patients 0 to 3 months of age compared to older pediatric patients. The pharmacokinetic parameters for pediatric patients, ages > 3 months to 15 years, are comparable to those obtained for adults. 

Bioavailability studies of 8 pediatric patients (11 to 15 years of age) showed a mean oral bioavailability of 0.5 compared to adult values of 0.42 to 0.49. Oral doses of 0.5 mg/kg achieved AUCs of 645 ± 249 ng-hr/mL and 580 ± 60 ng-hr/mL in pediatric patients < 1 year of age (N=5) and in pediatric patients 11 to 15 years of age, respectively, compared to 482 ± 181 ng-hr/mL in adults treated with 40 mg orally.
It is intended to provide a cosmetic product which can improve skin fitness and skin moisture by applying it on the skin. To achieve the object, the cosmetic product of the invention is characterized by forming a micro-vessel or capsule with hyaluronic acid, encapsulating collagen and ceramide in the microcapsule, and incorporating the microcapsule, in which collagen and ceramide are encapsulated, in a gelled basic cosmetic product in an amount of 0.1 to 5% by weight. Here, the gelled basic cosmetic product preferably contains ceramide, collagen, hyaluronic acid, vitamin C, Laminaria chroleuca extract and Pelvetia canaliculata extract. With the cosmetic product of the invention, the microcapsule itself penetrates into the skin and exerts a moisturizing effect from the inside of the skin. On the other hand, the ceramide, collagen or hyaluronic acid contained in the gelled basic cosmetic product exerts a moisturizing effect from the outside of the skin. That is, according to the invention, a moisturizing effect is exerted from the outside and the inside of the skin.
Upper GI tract symptoms are evaluated. Patients are asked to report to gastroenterologist if they have persistent ulcer symptoms and to report to the emergency room if they have evidence of GI bleeding or ulcer complications (melena, hematemesis, or sudden onset of severe epigastric pain). Endoscopy will be undergone to document any gastroduodenal ulcers with or without ulcer complications. If the hemoglobin level has decreased by 2g/dL or more, or stool check shows occult blood at each visit, endoscopy will be undergone to check the presence of gastroduodenal ulcers with or without bleeding. Patients without persistent ulcer symptoms or without evidence of ulcer complications will be invited to undergone scheduled endoscopy at the 3-month end of follow-up in each subjective.
PURPOSE:To provide the titled plaster capable of keeping the drug concentration in blood at a high level for a long period, by using mequitazine as an active component and a sticking base having a mequitazine-solubility of lower than a specific level at room temperature. CONSTITUTION:The objective long-acting anti-allergic plaster can be produced by using a sticking layer containing mequitazine [10-(3-quinuclidinemethyl) phenothiazine] and a sticking base and laminating the sticking layer to a substrate. The sticking base is selected to have a mequitazine-solubility of <=10wt% at normal temperature. The substrate is preferably a light-shielding material, i.e. having a light transmission of <=1% at 200-600nm wavelength measured by conventional ultraviolet and visible light absorption photometer. Since the solubility of mequitazine is <=10t% at normal temperature, the barrierness of skin to mequitazine is lowered to provide high drug concentration in blood. Furthermore, the plaster has low skin irritation.
The aim of this study is to compare standard education (doctor and nurse led) with Virtual Reality (VR) augmented education in patients prior to implantation of a permanent pacemaker. A 360° education video was prepared in the operating theatre and other areas of the hospital to make patients more comfortable with these unfamilliar places. The procedure was explained in details by a doctor and animations were used to help patients to visualise the procedure. Risks and complications of the procedure were highlited along with the precautionary measures patients need to take after the procedure.

Patients coming into the One-Day Cardilogy Unit of Podlesi Hospital will be randomised into 2 groups: Standard education and VR augmented education. The VR group will be then educated using VR and will be given an opportunity to ask a physician more questions if needed. Patients will then fill in forms to assess their experience, feelings and knowledge about the procedure. Data will be then collected to assess if VR could facilitate patients' education. The investigators believe it could be a useful tool to save time of doctors and nurses which is becoming more and more precious and expensive.
A system for generating a descriptor trail using artificial intelligence. The system includes at least a server configured to receive at least a biological extraction. At least a server is configured to generate a prognostic output as a function of at least a biological extraction. At least a server is configured to generate an ameliorative output as a function of a prognostic output. The system includes a descriptor generator module operating on at least a server. A descriptor generator module is configured to generate at least a descriptor trail from a descriptor trail data structure wherein the descriptor trail further comprises at least an element of diagnostic data.
Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 6 during primary treatment and 40 mg (dose level 1) then 60 mg (dose level 2-4) during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m\^2 on Day 1, and ibrutinib oral dose of 420 or 560 mg once daily on Day 1 to 28 during primary treatment for Cycle 1 to 6. Participants will also receive ibrutinib oral dose of 420 mg once daily at all dose levels during continuous treatment.
Prior evidence suggests that altered energy metabolism plays a crucial role in the development of fibrotic diseases. Recent research indicates that systemic sclerosis (SSc) patients have potentially benefited from energy management, implying that basal metabolic rate (BMR), a vital energy metabolic parameter, may be related to SSc. However, the causal effect of BMR on SSc remains unknown. Thus, we aimed to elucidate the causal links between BMR and SSc. Based on summary statistics from the genome-wide association studies (GWAS) database, two-sample Mendelian randomization (MR) was applied to explore causality between BMR and SSc. The causal relationships were assessed employing inverse variance weighted (IVW), MR-Egger, and weighted median (WM) methods. Meanwhile, several sensitivity analyses were carried out to ensure the robustness of the findings. There was an underlying genetic association of BMR on SSc (OR = 0.505, 95% CI: 0.272-0.936, P = 0.030). Moreover, no significant causal effect between SSc and BMR was observed in the reverse MR analysis (OR = 0.999, 95% CI: 0.997-1.001, P = 0.292). According to the sensitivity analysis, the presence of heterogeneity and genetic pleiotropy was not detected. Our findings, derived from a genetic perspective, provide robust evidence of a causal connection between BMR and SSc. To verify these results and clarify the potential mechanisms, further research is warranted.
Children will receive music practice lessons in groups, "Orchestra in Class" (4 different string instruments, violin, viola, cello, double bass) in school class size groups over 2 full years. Interventions, given by 2 professional teachers per class, take place for 1 hour and 30 minutes per week, completed by daily homework (20-30 minutes).
Research procedures involving patients will be limited to medical record review. This medical record review will help inform the intervention directed at PICU clinicians/stakeholders and the assessment of study outcomes. Approximately 50,000 patients will participate in the study. Data elements will be collected at each site and stored as password-protected Comma-separated values (CSV) files. These files will not contain any direct Protected Health Information (PHI) but will contain elements of date (e.g., date of admission, date of suspected sepsis episode). The study Identification (ID) number will be used to identify each unique patient. Each site will collect and store data in compliance with the Children's Hospital of Philadelphia (CHOP) and local Institutional Review Board (IRB) policies.
Cancer stem cells (CSCs) represent both a key driving force and therapeutic target of tumoral carcinogenesis, tumor evolution, progression, and recurrence. CSC-guided tumor diagnosis, treatment, and surveillance are strategically significant in improving cancer patients' overall survival. Due to the heterogeneity and plasticity of CSCs, high sensitivity, specificity, and outstanding targeting are demanded for CSC detection and targeting. Nanobiotechnologies, including biosensors, nano-probes, contrast enhancers, and drug delivery systems, share identical features required. Implementing these techniques may facilitate the overall performance of CSC detection and targeting. In this review, we focus on some of the most recent advances in how nanobiotechnologies leverage the characteristics of CSC to optimize cancer diagnosis and treatment in liquid biopsy, clinical imaging, and CSC-guided nano-treatment. Specifically, how nanobiotechnologies leverage the attributes of CSC to maximize the detection of circulating tumor DNA, circulating tumor cells, and exosomes, to improve positron emission computed tomography and magnetic resonance imaging, and to enhance the therapeutic effects of cytotoxic therapy, photodynamic therapy, immunotherapy therapy, and radioimmunotherapy are reviewed.
A DNA fragment distinct from the epidermal growth factor receptor (EGF-R) and $i(erb)B-2 genes was detected by reduced stringency hybridization of v-$i(erb)B to normal genomic human DNA. Characterization of the cloned DNA fragment mapped the region of v-$i(erb)B homology to three exons with closest homology of 64 % and 67 % to a contiguous region within the tyrosine kinase domains of theEGF-R and $i(erb)B-2 proteins, respectively. cDNA cloning revealed a predicted 148 kd transmembrane polypeptide with structural features identifying it as a member of the $i(erb)B family, prompting designation of the new gene as $i(erb)B-3. It was mapped to human chromosome 12q11-13 and was shown to be expressed as 6.2 kb transcript in a variety of normal tissues of epithelial origin. Markedly elevated $i(erb)B-3 mRNA levels were demonstrated in certain human mammary tumor cell lines. These findings indicate that increased $i(erb)B-3 expression, as in the case of EGF-R and $i(erb)B-2, plays a role in some human malignancies.
This product contains FD&C Yellow No. 6 which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 6 sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

General

Increasing the dose does not increase the diuresis and may increase the incidence of drowsiness and/or paresthesia. Increasing the dose often results in a decrease in diuresis. Under certain circumstances, however, very large doses have been given in conjunction with other diuretics in order to secure diuresis in complete refractory failure.